DK374087D0 - Fremgangsmaade til fremstilling af proteiner med faktor viii-aktivitet ved hjaelp af mikrobielle voertsceller og ekspressionsvektorer, vaertsceller og antistoffer til anvendelse ved denne - Google Patents

Fremgangsmaade til fremstilling af proteiner med faktor viii-aktivitet ved hjaelp af mikrobielle voertsceller og ekspressionsvektorer, vaertsceller og antistoffer til anvendelse ved denne

Info

Publication number
DK374087D0
DK374087D0 DK374087A DK374087A DK374087D0 DK 374087 D0 DK374087 D0 DK 374087D0 DK 374087 A DK374087 A DK 374087A DK 374087 A DK374087 A DK 374087A DK 374087 D0 DK374087 D0 DK 374087D0
Authority
DK
Denmark
Prior art keywords
cells
antibodies
procedure
expression vectors
factor viii
Prior art date
Application number
DK374087A
Other languages
English (en)
Other versions
DK374087A (da
Inventor
Ooyen Albert Johannes Jose Van
Peter Michael Andreoli
Mourik Jan Aart Van
Hans Pannekoek
Original Assignee
Gist Brocades Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868617594A external-priority patent/GB8617594D0/en
Priority claimed from GB868630699A external-priority patent/GB8630699D0/en
Application filed by Gist Brocades Nv filed Critical Gist Brocades Nv
Publication of DK374087D0 publication Critical patent/DK374087D0/da
Publication of DK374087A publication Critical patent/DK374087A/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • C12N15/625DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/78Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Pseudomonas
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745Assays involving non-enzymic blood coagulation factors
    • G01N2333/755Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK374087A 1986-07-18 1987-07-17 Fremgangsmaade til fremstilling af proteiner med faktor viii-aktivitet ved hjaelp af mikrobielle voertsceller og ekspressionsvektorer, vaertsceller og antistoffer til anvendelse ved denne DK374087A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868617594A GB8617594D0 (en) 1986-07-18 1986-07-18 Preparation of biologically active proteins
GB868630699A GB8630699D0 (en) 1986-12-23 1986-12-23 Preparation of biologically active proteins

Publications (2)

Publication Number Publication Date
DK374087D0 true DK374087D0 (da) 1987-07-17
DK374087A DK374087A (da) 1988-01-19

Family

ID=26291059

Family Applications (1)

Application Number Title Priority Date Filing Date
DK374087A DK374087A (da) 1986-07-18 1987-07-17 Fremgangsmaade til fremstilling af proteiner med faktor viii-aktivitet ved hjaelp af mikrobielle voertsceller og ekspressionsvektorer, vaertsceller og antistoffer til anvendelse ved denne

Country Status (9)

Country Link
EP (1) EP0253455A1 (da)
JP (1) JPS63313587A (da)
AU (1) AU620315B2 (da)
DK (1) DK374087A (da)
FI (1) FI873162A (da)
IL (1) IL83192A (da)
NO (1) NO872932L (da)
NZ (1) NZ221119A (da)
PT (1) PT85349B (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US5543145A (en) * 1984-09-17 1996-08-06 Baxter International, Inc. Pharmaceutical composition and method for the suppression of factor VIII inhibitor production
JPS62502589A (ja) * 1985-04-11 1987-10-08 ザ・チヤイルドレンズ・メデイカル・センタ−・コ−ポレ−シヨン フオン・ビルブラント因子
US5278066A (en) * 1985-08-09 1994-01-11 Gist-Brocades Nv Molecular cloning and expression of gene encoding lipolytic enzyme
KR910006424B1 (ko) * 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
FI98829C (fi) * 1986-01-27 1997-08-25 Chiron Corp Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
US5595886A (en) * 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
FR2613379B2 (fr) * 1987-04-03 1990-04-06 Transgene Sa Procede de preparation de fragments du facteur viii a partir de cellules de mammiferes
IL84168A0 (en) * 1986-10-15 1988-03-31 Rorer Int Overseas Human factor viii-c analogs,process for the preparation thereof and pharmaceutical compositions containing the same
US5830735A (en) * 1987-03-06 1998-11-03 Gist-Brocades Nv Method for producing lipolytic enzymes using transformed Pseudomonas
US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
EP0294910B1 (en) * 1987-06-12 1996-09-11 Immuno Ag Novel proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
AU627150B2 (en) * 1987-06-12 1992-08-20 Immuno Ag Novel proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IL86693A (en) * 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins that have the activity IIIV of the blood, a process for their preparation that uses cells are produced through genetic engineering and pharmaceutical preparations that contain them
DE3720246A1 (de) * 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) * 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
CA1340740C (en) * 1987-12-08 1999-09-14 Eileen R. Mulvihill Co-expression in eukaryotic cells
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
GB2214508A (en) * 1988-01-27 1989-09-06 Bayer Ag Plasmid vector for the efficient expression of foreign genes fused with newly conceived transcriptional and translational signal sequences.
CA2030554C (en) * 1989-06-29 2001-08-28 Wilhelmus J. Quax Mutant microbial .alpha.-amylases with increased thermal, acid, and/or alkaline stability
US5336760A (en) * 1989-09-14 1994-08-09 Baxter International Inc. Method and useful apparatus for preparing pharmaceutical compositions
FR2657884B1 (fr) 1990-02-05 1994-09-02 Tm Innovation Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
US5661008A (en) * 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
SE468050C (sv) * 1991-03-15 1998-02-11 Pharmacia & Upjohn Ab Rekombinant derivat av human faktor VIII
DK53792D0 (da) * 1992-04-24 1992-04-24 Novo Nordisk As Fremgangsmaade til fremstilling af proteiner
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US5910481A (en) * 1995-11-13 1999-06-08 Immuno Ag Hybrid proteins with modified activity
GB9907461D0 (en) 1999-03-31 1999-05-26 King S College London Neurite regeneration
CA2276091A1 (en) * 1996-12-27 1998-07-09 Mochida Pharmaceutical Co., Ltd. Cell membrane-directed drugs
US8372620B2 (en) 1998-12-23 2013-02-12 Dupont Nutrition Biosciences Aps Bacterial xylanases
GB0020498D0 (en) 2000-08-18 2000-10-11 Sterix Ltd Compound
JP4878428B2 (ja) 2000-09-21 2012-02-15 ベーアーエスエフ・アクチエンゲゼルシャフト タラロマイセスのキシラナーゼ
KR20030085112A (ko) 2000-12-07 2003-11-03 디에스엠 아이피 어셋츠 비.브이. 카르복시 말단 프롤린 잔기를 갖는 펩티드가 풍부한단백질 가수분해물
DE60103174T2 (de) 2000-12-07 2005-05-12 Dsm Ip Assets B.V. Verfahren zur verhinderung oder verminderung der trübung in getränken
GB0116453D0 (en) 2001-07-05 2001-08-29 Imp College Innovations Ltd Method
EP1418810A4 (en) 2001-08-03 2006-08-02 Us Gov Health & Human Serv TREATMENT OF HEMOPHILIA ORAL
BR0311655A (pt) 2002-06-07 2005-03-15 Dsm Ip Assets Bv Método melhorado para a prevenção ou redução de turbidez em bebidas
TWI328612B (en) 2002-07-25 2010-08-11 Dsm Ip Assets Bv Genes and their encoded polypeptides involved in the biosynthetic pathway of vitamin b12, vectors and host cells comprising the genes, and process for producing vitamin b12
GB0403864D0 (en) 2004-02-20 2004-03-24 Ucl Ventures Modulator
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
ES2755775T3 (es) 2005-11-28 2020-04-23 Dsm Ip Assets Bv Preparación de enzima que produce un sabor puro
GB0600406D0 (en) 2006-01-10 2006-02-15 Univ Bath Crystal
CN101636489B (zh) 2007-02-20 2014-08-13 帝斯曼知识产权资产管理有限公司 新颖的唾液酸酶
EP2126060B1 (en) 2007-03-22 2016-10-05 DSM IP Assets B.V. Novel lysyl oxidases
WO2011095604A1 (en) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
WO2011101339A2 (en) 2010-02-18 2011-08-25 Dsm Ip Assets B.V. Fermentation broth and filtration filter cake and uses thereof
WO2012007446A1 (en) 2010-07-13 2012-01-19 Dsm Ip Assets B.V. Use of a mutarotase in the production of dried powders
WO2012007445A1 (en) 2010-07-13 2012-01-19 Dsm Ip Assets B.V. Mutarotase in crystallization

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK165506C (da) * 1984-01-12 1993-04-19 Chiron Corp Proteinpraeparat med koagulationsaktivitet samt fremgangsmaade til fremstilling deraf
ZA852099B (en) * 1984-03-26 1985-12-24 Meloy Lab Recombinant factor viii-c.
IL74909A (en) * 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
FI98829C (fi) * 1986-01-27 1997-08-25 Chiron Corp Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta

Also Published As

Publication number Publication date
FI873162A (fi) 1988-01-19
JPS63313587A (ja) 1988-12-21
AU7575487A (en) 1988-01-21
IL83192A0 (en) 1987-12-31
NO872932L (no) 1988-01-19
AU620315B2 (en) 1992-02-20
PT85349B (pt) 1990-04-30
EP0253455A1 (en) 1988-01-20
FI873162A0 (fi) 1987-07-17
NO872932D0 (no) 1987-07-14
NZ221119A (en) 1990-08-28
IL83192A (en) 1992-11-15
DK374087A (da) 1988-01-19
PT85349A (en) 1987-08-01

Similar Documents

Publication Publication Date Title
DK374087D0 (da) Fremgangsmaade til fremstilling af proteiner med faktor viii-aktivitet ved hjaelp af mikrobielle voertsceller og ekspressionsvektorer, vaertsceller og antistoffer til anvendelse ved denne
DE68917323D1 (de) Expressions-Vektor für Fusions-Proteine und Immunogen-Proteine.
DE3587549T2 (de) Ergänzungstestverfahren von proteine bindenden enzymen.
DE3888921D1 (de) Polypeptide.
NO881658L (no) Biofunksjonelle proteiner.
GB8501473D0 (en) Cloned dna sequences
NO882226D0 (no) Fibrinolytiske proteiner.
NO885013D0 (no) FremgangsmŸte for fremstilling av bionedbrytbare mikrokapsler av vannopplelige peptider og proteiner, samt mikroka psler oppnŸdd ved fremgangsmŸten.
NO174970C (no) Rekombinant DNA, rekombinant DNA-vektor samt vertscelle
DK490888A (da) Immunoassay og biologiske konstruktioner til anvendelse ved denne
DK41590A (da) Forbedrede protein c-molekyler samt fremgangsmaade til fremstilling og aktivering af samme
NO881548D0 (no) Genteknologisk fremgangsmaate for fremstilling av polypeptider.
DK723488D0 (da) Fremgangsmaade til rekombinant udtrykkelse af zymogene former af humant protein c samt vektorer, dna-forbindelser og transformanter til brug ved fremgangsmaaden
NO871137L (no) Ikke-betennelsesfremkallende hyaluronsyrefraksjon og fremgangsmaate for fremstilling av denne.
NO169819C (no) Fremgangsmaate for fremstilling av hybrid polypeptid og dna-molekyl for bruk i denne
DK341485D0 (da) Faktor viii-r protein og fremgangsmaade til fremstilling heraf ved rekombinant-dna-syntese
DK623188D0 (da) Fremgangsmaade til inkubation af rekombinante proteinekspressionsceller
NO178036C (no) Fremgangsmåte for fremstilling av fusjonsproteiner, genstruktur, vektorer streptomycetceller og fusjonsproteinene
DE3780855D1 (de) Zellkultur-methode.
DK116487A (da) Fremgangsmaade til eksponering af en epitop i et protein med bestemt polypeptidstruktur, samt vektorer til brug ved fremgangsmaaden, hybridproteiner omfattende epitopen, og anvendelse af hybridproteinet ved diagnoser.
DK279587A (da) Fremgangsmaade til fremstilling af mikrobaerere for dyrkning af celler, og mikrobaerere fremstillet ved denne fremgangsmaade
DE3773651D1 (de) Probenladegeraet.
DE59009060D1 (de) Überexpression von Proteinen in rekombinanten Wirtszellen.
ZA875267B (en) Method for the preparation of proteins with factor viii activity by microbial host cells;expression vectors,host cells,antibodies
NO882836L (no) Fremgangsmaate for kjemisk modifisering av protider (proteiner og peptider).

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment